Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will report fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before the U.S. market opens. Management will host a conference call and live webcast at 8:30 am ET that day to discuss results and provide a business update.
According to the company, the live webcast is available at the provided webcast link and a replay will be accessible for at least 30 days on the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – KRYS
In the Feb 10 session, KRYS declined 0.70%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Clinical update | Positive | +1.0% | Positive interim KB407 Phase 1 CORAL-1 data in cystic fibrosis patients. |
| Jan 07 | Clinical call notice | Neutral | -1.2% | Announcement of investor call to share interim CORAL-1 KB407 clinical data. |
| Jan 05 | Conference participation | Neutral | -0.9% | Participation and presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 26 | Conference participation | Neutral | +0.8% | Presentation and investor meetings at the 8th Annual Evercore Healthcare Conference. |
| Nov 03 | Earnings release | Positive | +0.2% | Third quarter 2025 financial and operating results including VYJUVEK revenue growth. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news events, including clinical updates and conferences, have been followed by relatively modest one-day price moves, with no clear pattern of sharp divergence from the apparent news tone.
Over the past several months, KRYS has reported multiple updates across clinical, corporate, and financial fronts. A positive interim KB407 Phase 1 CORAL-1 update on Jan 8, 2026 was associated with a modest +1.03% move. Conference participation in early 2026 and late 2025 saw small price changes around 1% or less. Third quarter 2025 financial results on Nov 3, 2025 also produced a limited +0.17% reaction. Against this backdrop, today’s earnings-date announcement fits into a pattern of information-driven but measured trading responses.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
